Chemotherapy plus atorvastatin for advanced ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests adding a common cholesterol medicine (atorvastatin) to standard chemotherapy for advanced ovarian cancer. The goal is to see if the combination can help your immune system fight the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 89 years old.
- Your cancer must be high-grade serous ovarian, fallopian tube, or primary peritoneal cancer at stage III or IV.
- You must not be scheduled for immediate surgery to remove the tumor (the plan is chemotherapy first).
- You must have adequate blood counts and liver/kidney function (your doctor will check this).
- You cannot be on a statin drug (like atorvastatin) already, and you cannot plan to use bevacizumab (Avastin) as part of your treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding telmisartan (a blood pressure medicine) to standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based drugs. The goal is to see if the combination can help control the cancer better.
This trial tests whether a structured exercise program, along with the cholesterol medicine atorvastatin, can improve outcomes in people with metastatic prostate, breast, ovarian, or kidney cancer. It may help by reducing inflammation and supporting physical function during cancer treatment.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This study tests whether a new targeted drug (distamab vedotin) combined with standard chemo (carboplatin) works better than chemo alone for women with advanced ovarian cancer that has high levels of HER2. It is for women who have not had chemotherapy yet and have already had surgery to remove the tumor.
This trial tests a combination of three drugs—pembrolizumab (Keytruda, an immunotherapy), bevacizumab (Avastin, a blood-vessel blocker), and oral cyclophosphamide (a chemotherapy pill)—for women with high-grade ovarian cancer who have only tiny bits of disease left after finishing their initial treatment.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.